From CNBC: 2024-11-12 16:53:47

Shares of Amgen dropped over 7% due to concerns over bone density loss data from an early-stage trial of their weight loss injection, MariTide. Analysts are divided on the potential safety risk, with more data needed. The drug is a monthly competitor in the weight loss market, with phase two trial results expected soon.

Data from a phase one study showed that MariTide at 420mg led to a 4% loss in bone mineral density over 12 weeks. The drug works by blocking a gut hormone receptor called GIP while activating an appetite-suppressing hormone called GLP-1. Analysts are uncertain about the bone mineral density loss as a potential risk associated with the drug.

Despite concerns, some analysts believe the data is a non-issue, citing fluctuations in bone density. Amgen is aware of the hypothetical concern of bone mineral density loss but does not believe it presents a significant risk over time. More data from a larger cohort of patients is needed to fully assess the safety profile of MariTide.

Wall Street is eagerly awaiting the full phase two trial data from Amgen on MariTide to determine the drug’s safety profile. The selling of Amgen shares is seen as an overreaction by some analysts, who believe the bone mineral density effect may normalize over time. Further analysis is required before making a definitive judgment on the drug’s safety profile.



Read more at CNBC: Amgen stock falls on weight loss drug’s bone density loss data